Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally. Massive data breach ...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on ...

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

Investing.com -- Abivax SA ADR (NASDAQ:ABVX) stock rose 2.6% in premarket trading Thursday after the clinical-stage biotechnology company announced the acceptance of 22 scientific abstracts for ...

Abivax SA ADR (NASDAQ:ABVX) shares rose 2.6% in premarket trading on Thursday after the clinical-stage biotechnology company announced that 22 scientific abstracts have been accepted for presentation ...

This article first appeared on GuruFocus. Abivax SA (XPAR:ABVX) is set to release its Q3 2025 earnings on Dec 15, 2025. The ...

Investing.com -- Abivax SA (EPA: ABVX) shares dipped after the company reported a wider net loss for the first nine months ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...